Do You Need a Prescription for Wegovy? Essential Information for Weight Loss Management

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes. Wegovy is a prescription-only medication in the United States, and there is no lawful route to it that skips a licensed prescriber. The Wegovy prescribing information carries a boxed warning for the risk of thyroid C-cell tumors, a list of contraindications, and a Medication Guide that must be dispensed with it — the regulatory architecture of a drug that requires a clinician to decide whether the benefit outweighs the risk for a specific person. That is also true of compounded semaglutide, which is prepared by a pharmacy only in response to a prescription written for an individual patient. The real question is not whether you need a prescription. It is what a prescriber has to evaluate before writing one, and what that evaluation is actually protecting you from.

Why Wegovy Cannot Be Sold Over the Counter

A medication becomes prescription-only when its safe use depends on professional judgment that a consumer cannot reasonably supply on their own. Wegovy meets that bar on several fronts at once. Its labeling opens with a boxed warning — the strongest warning the FDA applies — stating that in rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures, and that whether it causes thyroid C-cell tumors including medullary thyroid carcinoma in humans has not been determined.

Because of that signal, Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma and in anyone with Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in people with known hypersensitivity to semaglutide or to any of the excipients in the product. Screening for a family cancer syndrome is not something a checkout page can do. It requires someone taking a history and knowing what to ask.

What Wegovy Is Actually Approved To Do

Wegovy injection is approved in combination with a reduced-calorie diet and increased physical activity for three purposes: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition; and, under accelerated approval, for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

Wegovy tablets, which sit inside the same prescribing information, carry a narrower set: cardiovascular risk reduction and long-term weight reduction in adults only. Each of those indications describes a population defined by diagnosis, not by a wish to weigh less. Determining whether someone falls inside one of them is a clinical act.

Compounded Semaglutide Requires a Prescription Too

Compounded semaglutide is sometimes described as an easier path, and that framing is wrong in a way worth correcting. A compounded preparation is made by a licensed pharmacy pursuant to a valid prescription for an identified individual patient. That prescription requirement is the legal definition of compounding, not an optional formality layered on top of it.

What is different is the regulatory status of the product itself. As the FDA explains in its compounding questions and answers, compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness, or quality before they are marketed. Wegovy and Ozempic are the FDA-approved semaglutide brands. A compounded preparation is not a generic version of either one, and it should never be described as equivalent to them.

What a Prescriber Reviews Before Writing It

A prescriber is looking at more than a number on a scale. The Wegovy label directs attention to acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, diabetic retinopathy complications, hypoglycemia when combined with insulin or an insulin secretagogue, and pulmonary aspiration during general anesthesia or deep sedation. Each of those maps onto a question about your history and your current medications.

Drug interactions matter as well. Because semaglutide delays gastric emptying, the label instructs prescribers to monitor the effects of oral medications taken alongside it and to consider increased clinical or laboratory monitoring for drugs with a narrow therapeutic index or that require monitoring. That instruction only works if someone knows your full medication list.

Pregnancy is a further gate. The label directs that Wegovy be discontinued in pregnant patients using it for weight reduction, and notes that because of semaglutide’s long half-life of approximately one week, the drug remains in circulation for roughly five to seven weeks after the last dose. Planning around that requires a conversation, not a form.

Telehealth Changes the Logistics, Not the Requirement

Online and asynchronous care has genuinely widened access. It has not removed the prescriber. A telehealth visit still involves a licensed clinician reviewing an intake, evaluating whether a GLP-1 medication is appropriate, and taking professional responsibility for the decision. Where the visit happens changes the convenience, not the standard.

That is the line to watch when comparing services. A legitimate provider will ask about thyroid cancer history, pancreatitis, gallbladder disease, kidney function, diabetic retinopathy, current medications, and pregnancy plans. A vendor that asks for none of those and ships a vial is not offering a shortcut through the prescription requirement — it is operating outside it.

Why Ongoing Follow-Up Is Part of the Same Answer

The prescription is a starting point rather than a transaction that closes. GLP-1 therapy is dosed over months, the labeled escalation schedules move in stepped intervals, and tolerability is the main variable that determines where a person settles. Someone has to be watching that, and it has to be someone who can change the plan.

This is also where the honest limits of any medication conversation sit. Two people with the same starting weight can respond very differently, and the label itself frames Wegovy as an adjunct to a reduced-calorie diet and increased physical activity rather than a replacement for them. In the registration trials, participants received structured dietary and activity counseling alongside the drug. The prescription is one component of a plan, not the plan itself.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Do you need a prescription for Wegovy?

Yes. Wegovy is a prescription-only medication in the United States. Its labeling carries a boxed warning for the risk of thyroid C-cell tumors, contraindications including a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, and a Medication Guide that must be dispensed with it. A licensed prescriber has to evaluate whether it is appropriate for you before it can be dispensed.

Does compounded semaglutide require a prescription?

Yes. Compounding is by definition the preparation of a medication by a licensed pharmacy pursuant to a valid prescription for an individual patient, so a prescriber is always involved. What differs is regulatory status: the FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. A compounded preparation is not a generic version of Wegovy or Ozempic and should not be described as equivalent to them.

Who is Wegovy not appropriate for?

The Wegovy prescribing information contraindicates it in people with a personal or family history of medullary thyroid carcinoma, in people with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with known hypersensitivity to semaglutide or the product excipients. The label also directs that it be discontinued in pregnant patients using it for weight reduction. Whether any of these applies to you is a determination for your clinician.

Can a telehealth provider prescribe Wegovy?

A licensed clinician practicing via telehealth can prescribe within the scope of their license and applicable state law. The evaluation standard does not change because the visit is online. Expect questions about thyroid cancer history, pancreatitis, gallbladder disease, kidney function, diabetic retinopathy, your current medication list, and pregnancy plans. A service that skips all of that is not shortening the process — it is skipping the evaluation.

What is the difference between Wegovy and Ozempic?

Both contain semaglutide, but they are separate products with separate labeling. Wegovy is approved for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, for long-term weight reduction, and for noncirrhotic MASH with moderate to advanced fibrosis. Ozempic is approved for glycemic control, cardiovascular risk reduction, and kidney outcomes in adults with type 2 diabetes. Ozempic has no weight-management indication.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.